Total Payments
$81,368
2024 Payments
$46,710
Companies
26
Transactions
123
Medicare Patients
10,442
Medicare Billing
$4.1M
Payment Breakdown by Category
Other$33,745 (41.5%)
Consulting$26,152 (32.1%)
Travel$17,217 (21.2%)
Food & Beverage$4,031 (5.0%)
Education$186.87 (0.2%)
Research$36.84 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,935 | 8 | 36.8% |
| Consulting Fee | $26,152 | 12 | 32.1% |
| Travel and Lodging | $17,217 | 45 | 21.2% |
| Food and Beverage | $4,031 | 50 | 5.0% |
| Honoraria | $3,810 | 2 | 4.7% |
| Education | $186.87 | 4 | 0.2% |
| Unspecified | $36.84 | 2 | 0.0% |
Payments by Type
General
$81,331
121 transactions
Research
$36.84
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30,063 | 24 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $7,975 | 10 | $0 (2024) |
| Seagen Inc. | $7,896 | 6 | $0 (2023) |
| Eisai Inc. | $7,857 | 14 | $0 (2024) |
| Exelixis Inc. | $6,735 | 17 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $5,532 | 7 | $0 (2024) |
| AstraZeneca UK Limited | $4,574 | 19 | $0 (2019) |
| GENZYME CORPORATION | $2,939 | 2 | $0 (2018) |
| TAIHO ONCOLOGY, INC. | $1,820 | 2 | $0 (2024) |
| Daiichi Sankyo Inc. | $1,510 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $46,710 | 54 | Merck Sharp & Dohme LLC ($26,288) |
| 2023 | $16,312 | 15 | Seagen Inc. ($7,896) |
| 2022 | $3,724 | 4 | Exelixis Inc. ($1,980) |
| 2021 | $1,707 | 6 | Ipsen Biopharmaceuticals, Inc ($1,400) |
| 2020 | $3,903 | 7 | Merck Sharp & Dohme Corporation ($3,650) |
| 2019 | $1,564 | 15 | AstraZeneca UK Limited ($1,044) |
| 2018 | $6,973 | 17 | AstraZeneca UK Limited ($3,530) |
| 2017 | $474.80 | 5 | Astellas Pharma US Inc ($123.55) |
All Payment Transactions
123 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,280.00 | General |
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $4,160.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $78.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $62.04 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $21.13 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $18.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $119.32 | General |
| 12/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $392.85 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $318.88 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $295.92 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $106.09 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $2,310.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $354.53 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $348.95 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $180.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $70.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $68.50 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $60.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $51.38 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $28.54 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/25/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $113.29 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC | AstraZeneca Pharmaceuticals LP | $36.84 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 68 | 3,368 | 184,869 | $10.8M | $1.8M |
| 2022 | 71 | 3,282 | 149,617 | $7.5M | $1.1M |
| 2021 | 62 | 2,682 | 113,792 | $5.9M | $1.0M |
| 2020 | 35 | 1,110 | 12,884 | $1.0M | $187,068 |
Total Patients
10,442
Total Services
461,162
Medicare Billing
$4.1M
Procedure Codes
236
All Medicare Procedures & Services
236 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 23 | 15,800 | $2.3M | $686,082 | 29.5% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 11 | 18,480 | $1.5M | $437,587 | 29.0% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 12 | 21,000 | $903,000 | $203,009 | 22.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 15 | 3,960 | $278,820 | $72,836 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 213 | 677 | $204,346 | $64,792 | 31.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 122 | 603 | $503,185 | $60,597 | 12.0% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 35 | 234 | $230,724 | $41,966 | 18.2% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 40 | 19,630 | $176,670 | $26,916 | 15.2% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 11 | 192 | $168,768 | $17,898 | 10.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 187 | 256 | $46,221 | $17,439 | 37.7% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 12 | 216 | $311,904 | $16,582 | 5.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 53 | 296 | $120,508 | $14,825 | 12.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 93 | 1,206 | $126,630 | $14,259 | 11.3% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 96 | 668 | $64,128 | $12,360 | 19.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 226 | 1,165 | $72,230 | $12,011 | 16.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 15 | 4,860 | $102,060 | $11,407 | 11.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 259 | 1,411 | $49,385 | $10,677 | 21.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 70 | 80 | $30,287 | $10,547 | 34.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 63 | 63 | $36,541 | $10,157 | 27.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 215 | 870 | $16,530 | $7,276 | 44.0% |
| 86301 | Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | Office | 2023 | 37 | 331 | $41,044 | $6,749 | 16.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 58 | $17,062 | $5,298 | 31.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 38 | 203 | $38,290 | $4,447 | 11.6% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 36 | 2,359 | $81,503 | $4,435 | 5.4% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 41 | 212 | $16,536 | $3,475 | 21.0% |
About Dr. Yue Zhang, MD
Dr. Yue Zhang, MD is a Hematology & Oncology healthcare provider based in Virginia Beach, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2010. The National Provider Identifier (NPI) number assigned to this provider is 1881906311.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yue Zhang, MD has received a total of $81,368 in payments from pharmaceutical and medical device companies, with $46,710 received in 2024. These payments were reported across 123 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($29,935).
As a Medicare-enrolled provider, Zhang has provided services to 10,442 Medicare beneficiaries, totaling 461,162 services with total Medicare billing of $4.1M. Data is available for 4 years (2020–2023), covering 236 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Virginia Beach, VA
- Active Since 07/13/2010
- Last Updated 01/19/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1881906311
Products in Payments
- KEYTRUDA (Biological) $30,263
- ADCETRIS (Biological) $7,896
- Lenvima (Drug) $7,857
- IMFINZI (Biological) $4,355
- Onivyde (Drug) $4,132
- CABOMETYX (Drug) $3,637
- JEVTANA (Drug) $2,939
- Cabometyx (Drug) $2,105
- LONSURF (Drug) $1,750
- COSELA (Drug) $1,500
- ONIVYDE (Drug) $1,400
- TEVIMBRA (Drug) $1,375
- IMFINZI (Drug) $184.28
- SIR-Spheres Microspheres (Device) $145.46
- Stivarga (Drug) $124.77
- KISQALI (Drug) $124.76
- Xtandi (Drug) $123.55
- Nexavar (Drug) $118.88
- XTANDI (Drug) $117.54
- Enhertu (Drug) $99.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Virginia Beach
Celesteann Bremer, M.d, M.D
Hematology & Oncology — Payments: $5,776
Hematology & Oncology $5,776
Gauri Radkar, D.o, D.O
Hematology & Oncology — Payments: $836.54
Hematology & Oncology $836.54
Dr. Bhaskar Rao, Md, MD
Hematology & Oncology — Payments: $325.56
Hematology & Oncology $325.56
Dr. Carolina Longa, Md, MD
Hematology & Oncology
Hematology & Oncology